# A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Study · id `cardio:ct-nct03723655` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03723655](<https://clinicaltrials.gov/study/NCT03723655>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03723655

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 314 participants.

## Technical summary

Registry record NCT03723655. Randomized; triple masking; primary purpose treatment. Start 2018-09-27 (actual); primary completion 2026-01-16 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 314 participants (enrolled count; ClinicalTrials.gov record NCT03723655, source copy `cardio:ctgov-nct03723655-2026-02-20`, retrieved 2026-10-31)
- Started: 2018-09-27 (actual) (ClinicalTrials.gov record NCT03723655, source copy `cardio:ctgov-nct03723655-2026-02-20`, retrieved 2026-10-31)
- Primary completion: 2026-01-16 (actual) (ClinicalTrials.gov record NCT03723655, source copy `cardio:ctgov-nct03723655-2026-02-20`, retrieved 2026-10-31)
- Completion: 2026-01-16 (actual) (ClinicalTrials.gov record NCT03723655, source copy `cardio:ctgov-nct03723655-2026-02-20`, retrieved 2026-10-31)
- Countries: United States; Belgium; Czechia; Denmark; France; Germany; Israel; Italy; Netherlands; Poland; Portugal; Spain; United Kingdom (ClinicalTrials.gov record NCT03723655, source copy `cardio:ctgov-nct03723655-2026-02-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03723655-2026-02-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- Condition: Hypertrophic Cardiomyopathy
- Condition: Obstructive Hypertrophic Cardiomyopathy
- Condition: Non-obstructive Hypertrophic Cardiomyopathy
- Intervention (Drug): mavacamten
- Lead sponsor: Bristol-Myers Squibb
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry intervention name matches this record: Mavacamten (`cardio:mavacamten`)
- Registry lists this organization as the lead sponsor: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

## Provenance

Content hash: b35f7bb864f5c65edda16367f6721c0f7df49d7e8f0cf00b00e20be679609264
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
